Latest Share Purchase Plans News

Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.

Burley Minerals has secured A$1 million through an oversubscribed Share Purchase Plan and placement, funding maiden drilling at its Pilbara iron ore project and lithium exploration in Canada.

ImpediMed has successfully closed an oversubscribed Share Purchase Plan, raising $2.1 million following a $13.2 million institutional placement. The strong shareholder response underscores confidence ahead of a key shareholder vote.

Sunshine Metals has agreed to sell its Hodgkinson Project to EQ Resources for $250,000, freeing up capital and management bandwidth to accelerate gold production at Mt Moss and exploration at Sybil.

Burley Minerals has closed its Share Purchase Plan (SPP) after receiving applications beyond the $300,000 target, following a recent $700,000 placement. The company may scale back or accept all applications at its discretion, with shares expected to be issued on 12 June 2026.

Tetratherix Limited (ASX:TTX) has launched a $2 million share purchase plan offering eligible Australian and New Zealand shareholders the chance to buy shares at a 2% discount to recent trading prices. The non-underwritten SPP opens on 4 June and closes on 18 June 2026.

Arafura Rare Earths has officially opened its share purchase plan following ASIC lodgement, while also dispatching notices for a July extraordinary general meeting in Perth.

Paradigm Biopharmaceuticals has successfully raised $21.375 million through an oversubscribed Share Purchase Plan and a recent placement, bolstering its balance sheet ahead of key Phase 3 trial milestones.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Sandon Capital has completed a $9 million conditional placement of notes, pending approval of a key Restructure Proposal by noteholders in June. The raise aims to support potential redemptions, working capital, and new investments.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Sunshine Metals has secured $7.7 million through an oversubscribed Share Purchase Plan, exceeding its $3 million target, to fund the Mt Moss processing facility acquisition and Liontown mine start-up.